PTC Therapeutics, Inc.

PTCT trades at an extraordinarily compressed 9.3x earnings—a stark discount to pharma peers—yet RSI sits elevated at 65.8, suggesting momentum-driven strength rather than fundamental repricing. With $6.1B market cap and 14% short interest, the stock displays classic squeeze characteristics: cheap valuation attracting value hunters while technical overbought conditions could invite profit-taking. The disconnect between attractive multiples and extended momentum creates tension; either the market is overlooking genuine catalysts justifying the discount, or valuation compression has already front-run near-term upside. Trading 52 weeks off highs adds another dimension—this could reflect legitimate headwinds or capitulation that's now pricing in excessive pessimism.